Clinical trials: Neuroepithelial Tumor
Glioblastomas
Feasibility Study of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT in Glioblastoma's Patients
This study is a non-randomized, prospective, multicentric feasibility study assessing 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT to differentiate early recurrence from post-radiation modifications in patients treated with radiotherapy…
- Trial name
- PAraDiGM (NCT03903419)
- Testing
- Feasibility study for the realization of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT for identification of early recurrence in patients treated with radiotherapy for glioblastoma.
- Where
- 2 sites in France
- Volunteers
- 16 people
- Sponsor
- Centre Leon Berard
DIPG Brain Tumor, Diffuse Intrinsic Pontine Glioma
Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG
A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cell with IL-7Ra signal targeting B7H3 in children with diffuse intrinsic pontine glioma (DIPG) patients after complete standard treatments.
- Trial name
- CMD03DIPG (NCT06221553)
- Testing
- B7H3 specific CAR T cell with IL-7Ra signaling domain
- Where
- Thailand
- Volunteers
- 9 people
- Sponsor
- Chulalongkorn University
Brain and Central Nervous System Tumors
Topotecan in Treating Patients With Recurrent Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of topotecan in treating patients with recurrent brain…
- Trial name
- NCT00003372
- Testing
- topotecan hydrochloride
- Where
- 11 sites in Canada
- Volunteers
- 17 people
- Sponsor
- NCIC Clinical Trials Group
IDH-mutant Glioma (Oligodendroglioma, Astrocytoma)
Amino Acid PET-based Response Assessment in IDH-mutant Gliomas (APPEAR)
Background: The radiological follow-up of diffuse gliomas is challenged by the difficult distinction of true progression from treatment-related changes.
- Trial name
- APPEAR (NCT07159607)
- Where
- 2 sites in Austria, Germany
- Volunteers
- 100 people
- Sponsor
- LMU Klinikum
Retinoblastoma, Refractory
Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma
Retinoblastoma (RB) is the most common intraocular malignancy in children, accounting for approximately 11% of all cancers diagnosed in children under the age of one.
- Trial name
- NCT06424301
- Testing
- Targeting NUDT21 siRNA drugs
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Recurrent Ependymoma
Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma
This study seeks to determine the optimum dose frequency of 5-Azacytidin (5-AZA) infusions into the fourth ventricle of the brain.
- Trial name
- 5-AZA (NCT03572530)
- Testing
- 5-Azacytidine (5-AZA) group 1, 5-Azacytidine (5-AZA) group 2, 5-Azacytidine (5-AZA) group 3
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- The University of Texas Health Science Center, Houston
Glioma, Glioblastoma
Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®
This is a phase 2, open-label clinical trial determining feasibility, safety, and tolerability of GammaTile® in elderly or frail subjects with newly diagnosed or recurrent malignant gliomas.
- Conditions
- Glioma, Glioblastoma, GBM, Glioma, Malignant
- Trial name
- ENDURANCE (NCT07821112)
- Testing
- GammaTile®
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Irvine
High-Grade Glioma (WHO III-IV)
FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade Glioma
This clinical trial aims to determine if FG001 can assist surgeons in identifying the difference between tumor and healthy tissue during surgery in participants with newly diagnosed high-grade glioma.
- Trial name
- NCT07609472
- Testing
- FG001
- Where
- 5 sites in United States
- Volunteers
- 76 people
- Sponsor
- FluoGuide A/S
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)
This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children with newly diagnosed DIPG or DMG. All patients will receive BXQ-350 by intravenous (IV) infusion and radiation therapy.
- Trial name
- KONQUER (NCT04771897)
- Testing
- BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance, BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
Carcinoma, Glioblastoma
MRinRT: Swansea University and SWWCC Collaboration Study.
The aim of this study is to learn whether using MRI (magnetic resonance imaging) scans to plan radiotherapy is better than using CT (computed tomography) scans alone.
- Conditions
- Carcinoma, Glioblastoma, Radiotherapy, MRI
- Trial name
- MRinRT (NCT07365124)
- Testing
- MRI
- Where
- United Kingdom
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Swansea Bay University Health Board
Malignant Glioma
AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma
The trial will address safety and tolerability of the combination of the IDH1R132H-specific vaccine with checkpoint blockade and seeks to explore predictive biomarkers for response to checkpoint blockade in post-treatment tumor…
- Trial name
- AMPLIFY-NEOVAC (NCT03893903)
- Testing
- IDH1R132H peptide vaccine, Avelumab
- Where
- 10 sites in Germany
- Volunteers
- 69 people
- Sponsor
- German Cancer Research Center
Brain and Central Nervous System Tumors
ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of glioblastoma multiforme.
- Trial name
- NCT00016991
- Testing
- gefitinib
- Where
- United States
- Sponsor
- Duke University
Glioblastoma
Glioblastoma Radiotherapy Using IMRT or Proton Beams
Radiation therapy is an integral part of the multimodal primary therapy of glioblastomas. As the overall prognosis in this tumor entity remains unfavorable, current research is focused on additional drug therapies, which are…
- Trial name
- GRIPS (NCT04752280)
- Testing
- Proton irradiation, Photon irradiation
- Where
- 3 sites in Germany
- Volunteers
- 326 people
- Sponsor
- University Hospital Heidelberg
Pineal Tumor
Melatonin Replacement Therapy in Pinealectomized Patients
This is an open-label, single-arm, single-center, proof-of-concept study to assess the effects of melatonin on cardiac autonomic activity in melatonin non-proficient pinealectomized patients.
- Trial name
- NCT03885258
- Testing
- Melatonin Replacement Therapy
- Where
- Brazil
- Volunteers
- 5 people
- Sponsor
- University of Sao Paulo
CNS Tumor, Artificial Intelligence (AI)
Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors
The goal of this observational study is to evaluate the feasibility and accuracy of a self-administered remote neurological examination using the "Iskhaa" mobile application in patients with brain tumors aged above 5 years who…
- Conditions
- CNS Tumor, Artificial Intelligence (AI), Glioma, Digital Health
- Trial name
- NEMO (NCT07236840)
- Testing
- Neurological assessment
- Where
- India
- Volunteers
- 600 people
- Sponsor
- Tata Memorial Centre
Glioblastoma
Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma
This study is evaluating a combination of drugs called sirolimus and vandetanib to treat glioblastoma. Sirolimus has been approved for use in patients who undergo organ transplants.
- Trial name
- NCT00821080
- Testing
- Sirolimus, Vandetanib
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Massachusetts General Hospital
Brain Tumor, Central Nervous System Tumor
Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006024
- Testing
- lomustine, temozolomide
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 32 people
- Sponsor
- Children's Oncology Group
Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
This phase III trial compares temporally-modulated pulsed radiation therapy versus standard radiation therapy in treating patients with newly diagnosed, IDH wildtype, MGMT-unmethylated glioblastoma.
- Trial name
- NCT07452458
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 54 sites in United States
- Volunteers
- 398 people
- Sponsor
- NRG Oncology
High Grade Glioma
Circulating Tumor DNA Collection From Patients With High Grade Gliomas
Improved outcomes for high-grade gliomas (HGG) require advances in our ability to monitor changes to tumour biology using non-surgical approaches.
- Trial name
- m-ctDNA (NCT05925218)
- Testing
- Radiotherapy as per standard of care
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- University Health Network, Toronto
Glioblastoma Multiforme
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
This is a Phase 1/2 study of selinexor in combination with standard of care (SoC) therapy for newly diagnosed glioblastoma (nGBM) or recurrent glioblastoma (rGBM).
- Trial name
- NCT04421378
- Testing
- Selinexor, Temozolomide (TMZ), Lomustine (CCNU)
- Where
- 18 sites in United States, Canada
- Volunteers
- 74 people
- Sponsor
- Karyopharm Therapeutics Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.